← Evidence map

ArticleClinical rheumatology2024

Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS.

Genki Kidoguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS. | Socratic